334 related articles for article (PubMed ID: 28008252)
1. Nanoscaled hydrated antimony (V) oxide as a new approach to first-line antileishmanial drugs.
Franco AM; Grafova I; Soares FV; Gentile G; Wyrepkowski CD; Bolson MA; Sargentini É; Carfagna C; Leskelä M; Grafov A
Int J Nanomedicine; 2016; 11():6771-6780. PubMed ID: 28008252
[TBL] [Abstract][Full Text] [Related]
2. Polarity-sensitive nanocarrier for oral delivery of Sb(V) and treatment of cutaneous leishmaniasis.
Lanza JS; Fernandes FR; Corrêa-Júnior JD; Vilela JM; Magalhães-Paniago R; Ferreira LA; Andrade MS; Demicheli C; Melo MN; Frézard F
Int J Nanomedicine; 2016; 11():2305-18. PubMed ID: 27307731
[TBL] [Abstract][Full Text] [Related]
3. Role of residual Sb(III) in meglumine antimoniate cytotoxicity and MRP1-mediated resistance.
Dzamitika SA; Falcão CA; de Oliveira FB; Marbeuf C; Garnier-Suillerot A; Demicheli C; Rossi-Bergmann B; Frézard F
Chem Biol Interact; 2006 Apr; 160(3):217-24. PubMed ID: 16524568
[TBL] [Abstract][Full Text] [Related]
4. Combination oral therapy against Leishmania amazonensis infection in BALB/c mice using nanoassemblies made from amphiphilic antimony(V) complex incorporating miltefosine.
Carregal VM; Lanza JS; Souza DM; Islam A; Demicheli C; Fujiwara RT; Rivas L; Frézard F
Parasitol Res; 2019 Oct; 118(10):3077-3084. PubMed ID: 31401656
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of antimony complexes of yeast mannan and mannan derivatives and their effect on Leishmania-infected macrophages.
Cantos G; Barbieri CL; Iacomini M; Gorin PA; Travassos LR
Biochem J; 1993 Jan; 289 ( Pt 1)(Pt 1):155-60. PubMed ID: 8424752
[TBL] [Abstract][Full Text] [Related]
6. Meglumine antımoniate-TiO2@Ag nanoparticle combinations reduce toxicity of the drug while enhancing its antileishmanial effect.
Abamor ES; Allahverdiyev AM; Bagirova M; Rafailovich M
Acta Trop; 2017 May; 169():30-42. PubMed ID: 28111133
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and characterization of bismuth(III) and antimony(V) porphyrins: high antileishmanial activity against antimony-resistant parasite.
Gomes ML; DeFreitas-Silva G; dos Reis PG; Melo MN; Frézard F; Demicheli C; Idemori YM
J Biol Inorg Chem; 2015 Jul; 20(5):771-9. PubMed ID: 25929728
[TBL] [Abstract][Full Text] [Related]
8. Species-specific antimonial sensitivity in Leishmania is driven by post-transcriptional regulation of AQP1.
Mandal G; Mandal S; Sharma M; Charret KS; Papadopoulou B; Bhattacharjee H; Mukhopadhyay R
PLoS Negl Trop Dis; 2015 Feb; 9(2):e0003500. PubMed ID: 25714343
[TBL] [Abstract][Full Text] [Related]
9. Antimonial drugs entrapped into phosphatidylserine liposomes: physicochemical evaluation and antileishmanial activity.
Borborema SE; Osso Junior JA; Andrade Junior HF; Nascimento Nd
Rev Soc Bras Med Trop; 2016 Apr; 49(2):196-203. PubMed ID: 27192589
[TBL] [Abstract][Full Text] [Related]
10. Profiling gene expression of antimony response genes in Leishmania (Viannia) panamensis and infected macrophages and its relationship with drug susceptibility.
Barrera MC; Rojas LJ; Weiss A; Fernandez O; McMahon-Pratt D; Saravia NG; Gomez MA
Acta Trop; 2017 Dec; 176():355-363. PubMed ID: 28843396
[TBL] [Abstract][Full Text] [Related]
11. Intraspecies susceptibility of Leishmania (Viannia) braziliensis to antileishmanial drugs: Antimony resistance in human isolates from atypical lesions.
Rugani JN; Quaresma PF; Gontijo CF; Soares RP; Monte-Neto RL
Biomed Pharmacother; 2018 Dec; 108():1170-1180. PubMed ID: 30372818
[TBL] [Abstract][Full Text] [Related]
12. 2'-Hydroxyflavanone activity in vitro and in vivo against wild-type and antimony-resistant Leishmania amazonensis.
Gervazoni LFO; Gonçalves-Ozório G; Almeida-Amaral EE
PLoS Negl Trop Dis; 2018 Dec; 12(12):e0006930. PubMed ID: 30521527
[TBL] [Abstract][Full Text] [Related]
13. Anti-leishmanial activity of heteroleptic organometallic Sb(v) compounds.
Ali MI; Rauf MK; Badshah A; Kumar I; Forsyth CM; Junk PC; Kedzierski L; Andrews PC
Dalton Trans; 2013 Dec; 42(48):16733-41. PubMed ID: 24077559
[TBL] [Abstract][Full Text] [Related]
14. Antimony susceptibility of Leishmania isolates collected over a 30-year period in Algeria.
Eddaikra N; Ait-Oudhia K; Kherrachi I; Oury B; Moulti-Mati F; Benikhlef R; Harrat Z; Sereno D
PLoS Negl Trop Dis; 2018 Mar; 12(3):e0006310. PubMed ID: 29561842
[TBL] [Abstract][Full Text] [Related]
15. Drug resistance in leishmaniasis: its implication in systemic chemotherapy of cutaneous and mucocutaneous disease.
Grogl M; Thomason TN; Franke ED
Am J Trop Med Hyg; 1992 Jul; 47(1):117-26. PubMed ID: 1322070
[TBL] [Abstract][Full Text] [Related]
16. Disposition of antimony in rhesus monkeys infected with Leishmania braziliensis and treated with meglumine antimoniate.
Friedrich K; Vieira FA; Porrozzi R; Marchevsky RS; Miekeley N; Grimaldi G; Paumgartten FJ
J Toxicol Environ Health A; 2012; 75(2):63-75. PubMed ID: 22129235
[TBL] [Abstract][Full Text] [Related]
17. Axenically grown amastigotes of Leishmania infantum used as an in vitro model to investigate the pentavalent antimony mode of action.
Sereno D; Cavaleyra M; Zemzoumi K; Maquaire S; Ouaissi A; Lemesre JL
Antimicrob Agents Chemother; 1998 Dec; 42(12):3097-102. PubMed ID: 9835497
[TBL] [Abstract][Full Text] [Related]
18. Complexes of different nitrogen donor heterocyclic ligands with SbCl3 and PhSbCl2 as potential antileishmanial agents against Sb(III)-sensitive and -resistant parasites.
Lizarazo-Jaimes EH; Reis PG; Bezerra FM; Rodrigues BL; Monte-Neto RL; Melo MN; Frézard F; Demicheli C
J Inorg Biochem; 2014 Mar; 132():30-6. PubMed ID: 24412095
[TBL] [Abstract][Full Text] [Related]
19. Polycaprolactone Antimony Nanoparticles as Drug Delivery System for Leishmaniasis.
Sousa-Batista AJ; Cerqueira-Coutinho C; do Carmo FS; Albernaz MS; Santos-Oliveira R
Am J Ther; 2019; 26(1):e12-e17. PubMed ID: 30601770
[TBL] [Abstract][Full Text] [Related]
20. Resistance to antimony and treatment failure in human Leishmania (Viannia) infection.
Rojas R; Valderrama L; Valderrama M; Varona MX; Ouellette M; Saravia NG
J Infect Dis; 2006 May; 193(10):1375-83. PubMed ID: 16619185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
